Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.88
+0.61 (7.38%)
At close: Nov 20, 2024, 4:00 PM
9.00
+0.12 (1.35%)
Pre-market: Nov 21, 2024, 7:39 AM EST
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $293.80M in the quarter ending September 30, 2024, with 8.61% growth. This brings the company's revenue in the last twelve months to $1.13B, up 2.05% year-over-year. In the year 2023, Emergent BioSolutions had annual revenue of $1.05B, down -6.10%.
Revenue (ttm)
$1.13B
Revenue Growth
+2.05%
P/S Ratio
0.41
Revenue / Employee
$703,438
Employees
1,600
Market Cap
481.16M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
Dec 31, 2019 | 1.11B | 323.60M | 41.36% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Treace Medical Concepts | 202.86M |
UroGen Pharma | 89.36M |
Theravance Biopharma | 63.19M |
Zevra Therapeutics | 24.49M |
Taysha Gene Therapies | 9.92M |
Perspective Therapeutics | 1.56M |
EBS News
- 12 days ago - Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic - Seeking Alpha
- 13 days ago - Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 - Benzinga
- 14 days ago - Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa - GlobeNewsWire
- 4 weeks ago - Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario - Seeking Alpha
- 2 months ago - Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts - GlobeNewsWire